Ernexa Therapeutics Inc 8-K/A, filed Sep 1, 2022
Ernexa Therapeutics Inc. (ERNA)
8-K/A
2022-09-01
For: 2022-07-21
View Original
Added on
April 06, 2026
About this 8-K/A
Ernexa Therapeutics Inc filed this 8-K/A on September 1, 2022, reporting on events of July 21, 2022.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 21, 2022
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (212 ) 582-1199
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading symbol
|
Name of each exchange on which registered
|
||
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange
Act of 1934:
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory Note
This Current Report on Form 8-K/A (this “Amendment”) is being filed as
an amendment to the Current Report on Form 8-K filed by Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “Company”), with the Securities and Exchange
Commission on July 27, 2022 (the “Original 8-K”). The purpose of this Amendment is to update the disclosure under “Item 5.02 Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers” of the Original 8-K to provide the effective date of Dr. Kevin D’Amour’s resignation as Chief Scientific Officer of the Company. As previously
reported, at the time of the Original 8-K, Dr. D’Amour had delivered his notice of resignation, but his date of resignation had not yet been determined. This Amendment additionally
includes a description and a copy of the separation agreement entered into by the Company and Dr. D’Amour on August 26, 2022. No other changes are being made to the Original 8-K.
| Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers.
|
On July 21, 2022, Dr. Kevin D’Amour, Chief Scientific Officer of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “Company”),
delivered his notice of resignation. Dr. D’Amour’s resignation became effective on August 26, 2022.
In connection with Dr. D’Amour’s resignation, on August 26,
2022, the Company entered into a Separation Agreement and General Release with Dr. D’Amour (the “Separation Agreement”), pursuant to which Dr. D’Amour resigned from his
positions as Chief Scientific Officer and as an officer, director and employee of the Company and all subsidiaries as of August 26, 2022. In consideration for Dr. D’Amour’s
execution of the Separation Agreement and non-revocation of a waiver and release of claims relating thereto, Dr. D’Amour will be entitled to the following benefits under the Separation Agreement:
| ● |
payment of Dr. D’Amour’s annual base salary for a period of nine (9) months after the expiration of
the applicable revocation period (the “Separation Period”), for a total gross amount equal to $311,250;
|
| ● |
payment of Dr. D’Amour’s premiums for continued health benefits provided under COBRA for the Separation Period; and
|
| ● |
the vested portions of all Dr. D’Amour’s outstanding options, representing 57,296 shares of the Company’s common stock, shall be eligible to be exercised for a period of ninety (90) days following the
separation date, and all unvested options, restricted stock units and performance stock units were immediately forfeited as of the separation date.
|
Under the Separation Agreement, Dr. D’Amour has agreed to cooperate with and assist the Company regarding certain matters and transitioning his employment duties and
responsibilities. Subject to certain exceptions and limitations, the Separation Agreement includes a general release of claims by Dr. D’Amour in favor of the Company and certain related persons and parties, and customary confidentiality provisions.
The Separation Agreement also includes certain other customary representations, warranties and covenants of Dr. D’Amour, and provides for reimbursement of certain expenses incurred by Dr D’Amour. The Separation Agreement supersedes all other
agreements or arrangements between Dr. D’Amour and the Company regarding the subject matter of the agreement, including those with respect to severance payments and benefits.
The foregoing description of the Separation Agreement is only a summary and is qualified in its entirety by reference to the full text of such
agreement, which is filed as Exhibit 10.1 to this Amendment and is incorporated by reference in this Item 5.02.
| Item 9.01 |
Financial Statements and Exhibits.
|
(d) Exhibits.
|
Exhibit
Number
|
Description
|
|
|
Separation Agreement and General Release, dated August 24, 2022, by and between
Brooklyn ImmunoTherapeutics, Inc. and Kevin D’Amour.
|
||
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
** Management contract or compensation plan or arrangement.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto
duly authorized.
|
Brooklyn ImmunoTherapeutics, Inc.
|
||
|
Dated: September 1, 2022
|
By:
|
/s/ Andrew Jackson
|
|
Chief Financial Officer
|
||
Exhibit 10.1
August 24, 2022
Kevin D’Amour
Via email
|
RE:
|
Separation Agreement and General Release
|
Dear Kevin:
The purpose of this separation agreement (the “Separation Agreement”)
is to memorialize the terms and conditions of the separation of your employment with Brooklyn ImmunoTherapeutics, Inc. (the “Company”) and its subsidiaries and affiliates (together with the Company collectively, the “Company
Group”), as well as that certain Executive Employment Agreement, dated June 5, 2021, by and between YOU (the terms “YOU” and “YOUR” refers to Kevin D’ Amour) and the Company (the “Employment Agreement”). Capitalized
terms used but not defined here in shall have the meanings ascribed thereto in the Employment Agreement.
To ensure that YOUR separation from the Company occurs on mutually acceptable terms,
this Separation Agreement, along with the General Release of Claims on Exhibit A, attached
hereto and made a part hereof (the “General Release”), will summarize the terms and conditions surrounding YOUR separation including, without limitation, the compensation, and benefits that will be provided
to YOU.
Separation Date
The effective date of the separation of YOUR employment, and the Employment Agreement,
is August 26, 2022 (“Separation Date”).
Resignation as Officer and Director of the Company Group
YOU acknowledge and agree that, effective as of the Separation Date, YOU will be deemed
to have resigned from all positions then held as an officer as well as a member of any board of directors, and any committee thereto, throughout the Company Group.
Accrued Obligations
Whether or not YOU choose to sign this Separation Agreement and the General Release,
the Company will pay to YOU any (a) accrued but unpaid base salary YOU have earned through the Separation Date, (b) accrued but unused paid time off through the Separation Date (c) reimbursement for unreimbursed business expenses properly incurred
by YOU pursuant to the Company’s applicable expense reimbursement policy; and (d) any accrued but unpaid benefits provided under the Company’s employee benefit plans, subject to and in accordance with the terms of those plans, in each case, less
applicable withholding and employment taxes, all of which shall be paid to YOU by the Separation Date or such other date as required under the applicable employee benefit plan.
For purposes of this Separation Agreement and the General Release, the amounts
described above in this section shall be referred to as the “Accrued Obligations”.
Separation Benefits
In the event that YOU execute and deliver to the Company both the Separation Agreement
and the General Release, and YOU do not revoke the General Release within the time period permitted by law (such period, the “Revocation Period” as defined below), the following shall apply (subject to any timing
restrictions as may be applicable under Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”)):
|
●
|
Commencing on the first regular payroll date immediately following the end of the Revocation
Period, the Company shall continue to pay to YOU YOUR annual base salary for a period of nine (9) months thereafter (the “Severance Period”) in accordance with the Company’s normal payroll processing, for a total gross
amount equal to $311,250 (less applicable income and employment tax withholdings).
|
| ● |
If YOU (or YOU and YOUR eligible dependents) timely and properly elects health insurance
continuation rights under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”), the Company will pay the cost of the COBRA premiums until the earlier of (i) the last day of the Severance Period or (ii) the termination of
YOUR rights under COBRA; provided, for the avoidance of doubt, that such covered dependents participated in the Company’s health plans prior to such separation, and provided, further, that if at any time the Company determines that its
payment of YOUR (or YOUR eligible dependents’ ) premiums would result in a violation of law, then in lieu of providing the premiums described above, the Company will instead pay YOU a fully taxable monthly cash payment in an amount equal
to the applicable premiums for such month, with such monthly payment being made on the last day of each month for the remainder of the Severance Period.
|
For purposes of this Separation Agreement and the General Release, the benefits
described above in this section shall be referred to as the “Separation Benefits”. Except for the Accrued Obligations, the payments from the Company to YOU pursuant to the terms of this Separation Agreement (including
the Separation Benefits) are not provided as a raise, bonus, or condition of YOUR employment with the Company.
10355 Science Center Drive, Suite 150, San Diego, CA 92121 | tel: (212) 582-1199 | brooklynitx.com
Mailing address: 10531 4S Commons
Drive, Suite 160-550, San Diego, CA 92127
2
YOU acknowledge and agree that as of the Separation Date, this Separation Agreement
and General Release shall supersede and replace all benefits, rights and obligations in connection with YOUR employment with the Company Group, except for those terms in the Employment Agreement that are specifically restated herein. Accordingly,
YOU further acknowledge and agree that this Separation Agreement and the General Release sets forth all compensation and benefits to which YOU are entitled and shall be paid to YOU in full satisfaction thereof, in connection with your
employment with the Company Group.
YOU also acknowledge and agree that the Separation Benefits to be paid under this
Agreement is due solely from the Company and that Insperity PEO Services, L.P. (“Insperity”), the professional employer organization retained by the Company, has no obligation to pay the Severance
benefits, even though its payment may be processed through Insperity.
Equity Awards
YOU acknowledge and agree that as of the Separation Date:
| ● |
The vested portion of the Option Grant (which specifically relates to 38,074 shares of the Company) shall be eligible to be exercised for a period of
ninety (90) days after the Separation Date pursuant to the terms and conditions of the Option Grant. The remainder of the Option Grant (which relates specifically to 102,506 shares of the Company) is unvested and shall be immediately forfeited as of the Separation Date.
|
| ● |
The unvested portion of the RSU Grant, which specifically relates to 52,717 shares of the Company, shall be immediately forfeited as of the Separation Date.
The vested portion of the RSU Grant, which specifically related to 17,573 shares
of the Company were previously vested pursuant to the terms and conditions of the RSU Grant.
|
| ● |
The outstanding portion of the performance stock units granted to YOU on March 11, 2022 (the “2022
PSU Award”), which specifically relates to 103,800 shares of the
Company, is unvested and shall be immediately forfeited as of the Separation Date. The remainder of the 2022 PSU Award, which specifically related to 34,600 shares of the Company, were previously forfeited prior to the Separation Date pursuant to the terms and condition of the 2022 PSU Award.
|
| ● |
The vested portion of the stock option granted to YOU on March 11, 2022 (the “2022
Option”) (which specifically relates to 19,222 shares of the
Company) shall be eligible to be exercised for a period of ninety (90) days after the Separation Date pursuant to the terms and conditions of the applicable stock option award agreement. The remainder of the 2022 Option (which relates
specifically to 119,178 shares of the Company) is unvested and shall be
immediately forfeited as of the Separation Date.
|
10355 Science Center Drive, Suite 150, San Diego, CA 92121 | tel: (212) 582-1199 | brooklynitx.com
Mailing address: 10531 4S Commons
Drive, Suite 160-550, San Diego, CA 92127
3
You acknowledge and agree that you do not have any rights with respect to any other
equity awards or equity-based interests in the Company.
Agreement Preparation and Negotiation Fees
Upon submission of invoices and other applicable documentation reasonably requested by
the Company, the Company shall reimburse you for reasonable attorneys’ fees and costs incurred by you in connection with your separation including the preparation and negotiation of this Separation Agreement and General Release, up to a maximum
amount of $5,000.
Integration of Employment Agreement; Survival of Certain Provisions
As of the Separation Date, YOU acknowledge and agree that this Separation Agreement shall supersede and replace the Employment
Agreement, except for those provision that are specifically restated and incorporated by reference herein, in addition to the following provisions under the Employment Agreement (collectively, the “Survival Provisions”):
Section 6 (Company Property) provided you will be entitled to keep and not obligated to return to the Company your work laptop so long as all of the Company property, documents and confidential information are removed from such laptop; Section 9
(Protection of Confidential Information); Section 10 (Intellectual Property); Section 11 (Publicity; Non-disparagement), except the parties agree that nothing in this Separation Agreement or the Employment Agreement prevents YOU from discussing or
disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that YOU have reason to believe is unlawful; Section 20 (Dispute Resolution) and Section 21 (Indemnification) which shall
remain in full force and effect except the parties agree that (a) individual claims under the Private Attorneys General Act can be subject to arbitration under that Section 20 and (b) the following claims are
excluded from the scope of that Section 20: (i) claims under the National Labor Relations Act, (ii) claims under the California Workers’ Compensation Act, (iii) claims for unemployment compensation benefits, (iv) claims for benefits under a plan that is governed by the Employee Retirement Income Security Act of 1974, (v) claims that are subject to the Ending
Forced Arbitration of Sexual Assault and Sexual Harassment Act, or (vi) claims that are expressly prohibited from mandatory arbitration under applicable law. Accordingly, YOU further acknowledge and agree that (i) this Separation Agreement sets
fo1th all compensation and benefits to which YOU are entitled under YOUR Employment Agreement; and (ii) in the event that YOU breach any of the Survival Provisions, the Separation Benefits shall cease immediately and YOU will no longer be
entitled to such benefits.
Release Of Claims Against The Company Group
In exchange for and as a condition to receiving the Separation Benefits, YOU shall
knowingly and willingly release the Company Group from any kind of claim YOU have arising out of or related to YOUR employment, the Employment Agreement and/or the termination of YOUR employment with the Company Group by executing the General
Release attached hereto as Exhibit A.
10355 Science Center Drive, Suite 150, San Diego, CA 92121 | tel: (212) 582-1199 | brooklynitx.com
Mailing address: 10531 4S Commons
Drive, Suite 160-550, San Diego, CA 92127
4
YOU will be required to execute the General Release, and therefore
agree to be bound by the terms and conditions thereof, no earlier than the Separation Date but no later than thirty (30) days after such Separation Date.
Cooperation/Assistance
Cooperation and Assistance: Upon
reasonable notice and at reasonable times, YOU agree to assist and cooperate with the Company, by telephone or video conference or otherwise, concerning business or legal related matters about which YOU possess relevant knowledge or information.
Such cooperation shall only be provided at the Company’s specific request and will include, but not be limited to, assisting or advising the Company with respect to any business-related matters or any actual or threatened legal action (including
testifying in depositions, hearings, and /or trials) about which YOU possess relevant knowledge or information. In addition, you agree to promptly inform the Company if any person or entity contacts YOU in an effort to obtain information about the
Company. The Company agrees to reimburse YOU for all reasonable and necessary costs and expenses incurred in connection with such cooperation and will compensate YOU at a reasonable rate for time spent by YOU at the Company’s request in connection
with such cooperation.
Severability; Entire Agreement; No Oral Modifications;
No Waivers
If a court of competent jurisdiction determines that any of the provisions of this
Agreement are invalid or legally unenforceable, all other provisions of this Agreement shall not be affected and are still enforceable. This Separation Agreement and the General Release are intended to be a single integrated contract expressing our
entire understanding regarding the subjects it addresses. As such, it supersedes all oral and written agreements, promises, representations and discussions that occurred before the time YOU sign each of them except as to any obligations YOU may
owe to the Company Group as described in the “Integration of Employment Agreement; Survival of Certain Provisions” section above that remain in effect and for the avoidance of doubt, no extrinsic evidence may be introduced in any judicial proceeding or arbitration involving this Separation Agreement. This Separation Agreement and
the General Release may be amended or modified only by an agreement in writing signed by YOU and counter signed by an executive officer of the Company. The failure by the Company or YOU (i) to declare a breach, or (ii) to otherwise assert rights
under this Agreement shall not be construed as a waiver of any of rights under this Separation Agreement and the General Release. This Separation Agreement and the General Release may be executed and delivered (including by facsimile or other
electronic transmission) in one or more counterparts, and by the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original, but all of which taken together shall constitute one and the same
instrument.
10355 Science Center Drive, Suite 150, San Diego, CA 92121 | tel: (212) 582-1199 | brooklynitx.com
Mailing address: 10531 4S Commons
Drive, Suite 160-550, San Diego, CA 92127
5
Governing Law; Venue
This Separation Agreement and the General Release shall be governed by the laws of the
State of California applicable to contracts executed and performed within that State and without respect to conflict of laws principles. The parties hereto irrevocably and unconditionally (i) agree that any suit, action or legal proceeding
arising out of or relating to this Agreement shall be brought in the courts of record of the State of California or the court of the United States, Southern District of California; and (ii) consent to the jurisdiction of each such court in any
suit, action or proceeding.
Acknowledgements and Certifications
YOU acknowledge and certify that:
| ● |
YOU have read and YOU understand all of the terms of this Separation Agreement and the General
Release on Exhibit A, and are not relying on any representation or
statement, written or oral, not set forth in this Separation Agreement and the General Release;
|
| ● |
YOU are signing this Separation Agreement, and shall sign the General Release, knowingly and
voluntarily;
|
| ● |
YOU have been advised to consult with an attorney before signing this Separation Agreement and the
General Release ;
|
| ● |
YOU have the right to consider the terms of this Separation Agreement and the General Release for
21 days; however, YOU do not have to take all 21 days to consider it, and if YOU take fewer than 21 days to review this Separation Agreement and the General Release, YOU expressly waive any and all rights to consider this Separation
Agreement and the General Release for the balance of the 21-day review period; and
|
| ● |
the General Release includes a release of any claim YOU might have under the ADEA (the “ADEA Claims”).
For seven (7) days after signing the General Release, YOU have the right to revoke YOUR release of ADEA Claims (the “Revocation Period”). To revoke YOUR release of ADEA Claims, the revocation or rescission
must be in writing and must be delivered by hand or sent by certified mail , return receipt requested, postmarked with in the seven (7) day period, and properly addressed to the Chairman of the Company at 10355 Science Center Drive,
Suite 150, San Diego, CA 92121. Revoking YOUR release of ADEA Claims shall result in the invalidation of this Separation Agreement, in its entirety, as of such revocation date; and
|
10355 Science Center Drive, Suite 150, San Diego, CA 92121 | tel: (212) 582-1199 | brooklynitx.com
Mailing address: 10531 4S Commons
Drive, Suite 160-550, San Diego, CA 92127
6
| ● |
YOU and the Company and Parent each agree that any changes that have been made to this Separation Agreement and the General Release from the versions
originally presented to YOU do not extend the 21-day period YOU have been given to consider this Separation Agreement and the General Release, whether those changes are deemed material or non-material.
|
IF YOU SIGN THIS DOCUMENT AND EXHIBIT A ATTACHED HERETO, IT BECOMES A LEGALLY ENFORCEABLE AGREEMENT EFFECTIVE ON THE DATE SIGNED
BY THE COMPANY.
|
Dated: August 26, 2022
|
/s/ KEVIN D’AMOUR
|
|
|
KEVIN D’AMOUR
|
||
|
Dated: August 26, 2022
|
BROOKLYN IMMUNOTHERAPEUTICS, INC.
|
||
| By: | /s/ Matt Angel | ||
| Name: Matt Angel |
|||
| Title: CEO |
|||
10355 Science Center Drive, Suite 150, San Diego, CA 92121 | tel: (212) 582-1199 | brooklynitx.com
Mailing address: 10531 4S Commons
Drive, Suite 160-550, San Diego, CA 92127
7
EXHIBIT A
GENERAL RELEASE OF CLAIMS
1. In exchange for the Separation Benefits described in that certain Separation and Release Agreement (the “Company”), dated August 24, 2022 (the “Separation Agreement”)
to which this General Release of Claims is attached as Exhibit A thereto, Kevin D’Amour (“Executive”), for himself and his family, heirs, executors, administrators, legal representatives and their respective
successors and assigns, does hereby release and forever discharge Brooklyn ImmunoTherapeutics, Inc. (the “Company”) and its subsidiaries, affiliated companies, successors and assigns (to get her with Company, the “Company
Group”) and Insperity PEO Services, L.P., the professional employer organization retained by the Company, and its current and former parent companies, subsidiaries and other affiliates (collectively, “Insperity”), and
their respective current or former directors, officers, employees, shareholders, insurers or agents in such capacities (collectively with the Company Group and Insperity, the “Released Parties”)
from any and all actions, causes of action, suits, controversies, claims and demands whatsoever, for or by reason of any matter, cause or thing whatsoever, whether known or unknown including, but not limited to, all claims under any
applicable laws arising under or in connection with Executive’s employment or termination thereof, and/or in connection with or arising under the Employment Agreement (as defined in the Separation Agreement), whether for tort, breach of express
or implied employment contract, wrongful discharge, intentional infliction of emotional distress, or defamation or injuries incurred on the job or incurred as a result of loss of employment. Executive acknowledges that the Company Group
encouraged him to consult with an attorney of his choosing, and through this General Release of Claims encourages him to consult with his attorney with respect to possible claims under the Age Discrimination in Employment Act (“ADEA’’) and
that he understands that the ADEA is a Federal statute that, among other things, prohibits discrimination on the basis of age in employment and employee benefits and benefit plans. Without limiting the generality of the release provided
above, Executive expressly waives any and all claims under ADEA that he may have as of the date hereof. Executive further understands that by signing this General Release of Claims he is in fact waiving, releasing and forever giving up any
claim under the ADEA as well as all other laws within the scope of this paragraph 1 that may have existed on or prior to the date hereof. Notwithstanding anything in this paragraph 1 to the contrary, this General Release of Claims shall
not apply to (i) any rights to receive any payments or benefits pursuant to the Separation Agreement, (ii) any rights or claims that may arise as a result of events occurring after the date this General Release of Claims is executed, (iii) any
indemnification rights Executive may have as a former officer or director of the Company Group, (iv) any claims for benefits under any directors’ and officers’ liability policy maintained by the Company Group in accordance with the terms of
such policy, (v) any indemnification rights set forth in the parties’ prior Employment Agreement; and (vi) any rights as a holder of equity securities of the Company.
2 Executive represents that he has not filed against the Released Parties any complaints, charges, or lawsuits arising out of his employment or under his Employment Agreement, or any
other matter arising on or prior to the date of this General Release of Claims, and covenants and agrees that he will never individually or with any person file, or commence the filing of, any charges, lawsuits, complaints or proceedings
with any governmental agency, or against the Released Parties with respect to any of the matters released by Executive pursuant to paragraph 1 hereof (a “Proceeding”); provided, however,
that
A-1
a Nothing in this Agreement prohibits or prevents the Executive from filing a charge with or participating, testifying, or assisting in any investigation, hearing, or other proceeding before the U.S. Equal
Employment Opportunity Commission, the National Labor Relations Board or a similar agency enforcing federal, state or local anti-discrimination laws. However, to the maximum extent permitted by law, the Executive agrees that if such an
administrative claim is made to such an anti-discrimination agency, he shall not be entitled to recover any individual monetary relief or other individual remedies. In addition, nothing in this Agreement, including but not limited to the
release of claims and non-disparagement clauses, prohibits the Executive from (A) reporting possible violations of federal law or regulations, including any possible securities laws violations, to any governmental agency or entity, including but
not limited to the U.S. Department of Justice, the U.S. Securities and Exchange Commission, the U.S. Congress, or any agency Inspector General; (B) making any other disclosures that are protected under the whistleblower provisions of federal law
or regulations; or (C) otherwise fully participating in any federal whistleblower programs, including but not limited to any such programs managed by the U.S. Securities and Exchange Commission and/or the Occupational Safety and Health
Administration. Moreover, nothing in this Agreement prohibits or prevents the Executive from receiving individual monetary awards or other individual relief by virtue of participating in such federal whistleblower programs.
b. Executive shall not have relinquished his right to
commence a Proceeding to challenge whether Executive knowingly and voluntarily waived his rights under ADEA.
3. Executive acknowledges that Executive has been advised to consult with legal counsel and is familiar with the provisions of California Civil Code section 1542, a statute that otherwise prohibits the release of unknown Claims,
which provides as follows:
A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES
NOT KNOW OR SUSPECTS TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR THE RELEASED PARTY.
Being aware of said code section, Executive agrees to expressly waive any rights
Executive may have thereunder, as well as under any other statute or common law principles of similar effect.
A-2
4. Executive here by acknowledges that the Company Group has informed him that he has up to twenty-one (21) days to sign this General Release of Claims and he may knowingly and voluntarily waive that twenty-one (21) day period by
signing this General Release of Claims earlier. Executive also understands that he shall have seven (7) days following the date on which he signs this General Release of Claims within which to revoke the release of ADEA claims by
providing written notice of his revocation to the Company Group (the “Revocation Period”).
5. Executive acknowledges that this General Release of Claims will be governed by and construed and enforced in accordance with the internal laws of the State of California applicable to contracts made and to be performed
entirely within such State.
6. Executive acknowledges that he has read this General Release of Claims,
that he has been advised that he should consult with an attorney before he executes this General Release of Claims, and that he understands all of its terms and executes it voluntarily and with full knowledge of its significance and the
consequences thereof.
7. This General Release of Claims shall take effect on the eighth day
following Executive’s execution of this General Release of Claims unless Executive delivers written revocation(s) to the Company within the aforementioned Revocation Period.
|
|
/s/ KEVIN D’AMOUR |
|
|
KEVIN D’AMOUR |
|
|
|
| August 26, 2022 |
|
A-3